---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-041896"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2021-08-06T23:59:59+00:00"
generated_at: "2026-06-29T20:39:04.682957+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Imara Q2 net loss $13.2M; IMR-687 SCD trial fully enrolled; interim data Q4 2021

## Summary
- Net loss $13.2M ($0.74/share) vs $10.2M ($0.59) in Q2 2020.
- Cash $66.8M at June 30; $50M July offering extends runway through 2022.
- SCD Phase 2b (Ardent) enrollment complete; primary analysis Q1 2022, interim Q4 2021.
- Beta-thalassemia Phase 2b (Forte) TDT cohort fully enrolled; interim data Q4 2021; NTDT half enrolled.
- Developing HFpEF Phase 2 protocol; FDA interaction planned Q4 2021; Laura Williams appointed to board.

## SEC filing metadata
- accession: 0001564590-21-041896
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2021-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000156459021041896/0001564590-21-041896-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000156459021041896/imra-8k_20210630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-041896
- JSON: https://secwatch.observer/filing/0001564590-21-041896.json
- Plain text: https://secwatch.observer/filing/0001564590-21-041896.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.